Kite Pharma expands and strengthens leadership team
Dr. Kivlighn has more than twenty-five years of experience in the pharmaceutical and biotech industry. Most recently, he was a Global Product Development Team leader at Medimmune, spearheading programs in oncology and autoimmunity, and prior to this was Head of Global Strategic Marketing.
Previously, Dr. Kivlighn was Head of New Product Planning / Commercial Analytical Process Owner at NABI Biopharmaceuticals. He began his career at Merck and Company, assuming roles of increasing responsibility for global marketing activities in diverse franchise areas. While at Merck, Dr. Kivlighn played a key role in the development, launch and brand management of Cozaar.
In addition, Dr. Kivlighn served as the U.S. commercial lead for the launch of RotaTeq, a vaccine for the prevention of rotavirus-induced gastroenteritis in children. Dr. Kivlighn has authored or co-authored more than 75 peer-reviewed articles and holds a B.S. in Distributed Studies from Iowa State University and a Ph.D. in Pharmacology from the University of Houston.
Dr. Polverino has substantial background and expertise in the immunotherapy field. He joins Kite from Amgen, most recently serving as Executive Director Research, Therapeutic Innovation Unit, a role in which he made significant contributions to advancing multiple clinical programs, including immunotherapy.
Previous positions at Amgen included Director Research, Department of Oncology Research. Dr. Polverino began his career as a scientist at Cold Spring Harbor Laboratory, and he has authored or co-authored more than 35 peer-reviewed articles. ■